Radiprodil

Radiprodil (INNTooltip International Nonproprietary Name; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures.^[1][2][3] It is taken orally.^[1] The drug is being developed by GRIN Therapeutics.^[1] As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures.^[1] The drug was first described in the scientific literature by 2003.^[4]

Other namesRGH-896; RGH896

Routes of
administrationOral^[1]

Drug classNR2B subunit-containing NMDA receptor negative allosteric modulator

CAS Number

• 496054-87-6

Quick facts Clinical data, Other names ...

Radiprodil

Clinical data
Other names	RGH-896; RGH896
Routes of administration	Oral[1]
Drug class	NR2B subunit-containing NMDA receptor negative allosteric modulator
Identifiers
IUPAC name 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide
CAS Number	496054-87-6
PubChem CID	10200813
DrugBank	DB12260
ChemSpider	8376312
UNII	5XGC17ZKUF
ChEMBL	ChEMBL182066
CompTox Dashboard (EPA)	DTXSID80964297
Chemical and physical data
Formula	C21H20FN3O4
Molar mass	397.406 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4
InChI InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28) Key:GKGRZLGAQZPEHO-UHFFFAOYSA-N

Close